Furthermore, after the downregulation of RTP801 expression, the levels of glial markers associated with pathology and key inflammatory proteins returned to normal, demonstrating that RTP801 could be a potential target for future Alzheimer’s disease therapies [153]. The gene discussed is DDIT4; the disease is Alzheimer disease.